The Los Angeles-based firm has raised $320 million to incubate and invest in early-stage life sciences companies — Seidenberg’s specialty.
A spokesperson for Westlake Village confirmed to TechCrunch this morning that she is in the process of “transitioning” out of Kleiner Perkins.
Seidenberg has been one of the most prominent female partners at the firm, as well as a leading biotech investor in Silicon Valley. She has incubated and served on the boards of 3-V Biosciences, Atara, Breathe Technologies, Epizyme, ExpansionRx, FLX, Hixme, Kinsa and more, according to her LinkedIn profile.
Kleiner Perkins COO Scott Ryles has also joined Westlake Village as its COO. And in January, Sean Harper, executive vice president and head of R&D at Amgen, will join the firm. Seidenberg previously served as the chief medical officer and head of global development at Amgen.
“This was the ideal time – both in my role at Kleiner Perkins and given the explosive growth of breakthroughs in science and medicine – to pursue my passion for life sciences and launch a fund with such an exceptional team with whom I’ve worked closely in prior roles,” Seidenberg said in a statement.